Key facts
- This page summarizes Thomas G. Wiggans's Form 4 filing for CymaBay Therapeutics, Inc..
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 22 Mar 2024, 16:54.
Thomas G. Wiggans - 22 Mar 2024 Form 4 Insider Report for CymaBay Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 22 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Mar 2024, 16:54:55 UTC
- Prior SEC filing
- 26 Jan 2024
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Quinlan, as attorney-in-fact for Thomas Wiggans
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas G. Wiggans filed Form 4 for CymaBay Therapeutics, Inc. on 22 Mar 2024.
Change
- Previous filing in this sequence was filed on 26 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CBAY
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -80,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 22 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $4.63
- Footnotes
- F1
CBAY
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -67,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 22 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,000
- Exercise price
- $2.94
- Footnotes
- F1
CBAY
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 22 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $7.80
- Footnotes
- F1
CBAY
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -14,010
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 22 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,010
- Exercise price
- $22.85
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Thomas G. Wiggans is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.